Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 234316, 5 pages
http://dx.doi.org/10.1155/2014/234316
Research Article

Proatherogenic Oxidized Low-Density Lipoprotein/2-Glycoprotein I Complexes in Arterial and Venous Disease

1Department of Medicine, Divisions of Cardiology and Hematology, New York University School of Medicine, New York, NY 10016, USA
2Department of Surgery, Division of Vascular Surgery, New York University School of Medicine, New York, NY 10016, USA
3Department of Chemistry, Indiana University, South Bend, IN 46634, USA
4Medical Department, Corgenix, Inc., 11575 Main Street, No. 400, Broomfield, CO 80020, USA

Received 10 August 2014; Revised 6 October 2014; Accepted 6 October 2014; Published 28 October 2014

Academic Editor: Xiao-Feng Yang

Copyright © 2014 Jeffrey S. Berger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig, “Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population,” Circulation, vol. 112, no. 5, pp. 651–657, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Matsuura, K. Kobayashi, M. Tabuchi, and L. R. Lopez, “Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis,” Progress in Lipid Research, vol. 45, no. 6, pp. 466–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Kobayashi, E. Matsuura, Q. Liu et al., “A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages,” Journal of Lipid Research, vol. 42, no. 5, pp. 697–709, 2001. View at Google Scholar · View at Scopus
  4. K. Kobayashi, M. Kishi, T. Atsumi et al., “Circulating oxidized LDL forms complexes with β 2-glycoprotein I: implication as an atherogenic autoantigen,” Journal of Lipid Research, vol. 44, no. 4, pp. 716–726, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. L. R. Lopez, D. F. Simpson, B. L. Hurley, and E. Matsuura, “OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: Pathogenic implications for vascular involvement,” Annals of the New York Academy of Sciences, vol. 1051, pp. 313–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Bassi, A. Ghirardello, L. Iaccarino et al., “OxLDL/β2GPI-anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients,” Autoimmunity Reviews, vol. 7, no. 1, pp. 52–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Pengo, E. Bison, A. Ruffatti, and S. Iliceto, “Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism,” Thrombosis Research, vol. 122, no. 4, pp. 556–559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. P. Greco, A. M. Conti-Kelly, T. Greco Jr. et al., “Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome,” American Journal of Clinical Pathology, vol. 132, no. 4, pp. 613–620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. T. P. Greco, A. M. Conti-Kelly, J. R. Anthony et al., “Oxidized-LDL/β2-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes,” American Journal of Clinical Pathology, vol. 133, no. 5, pp. 737–743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. R. Ames, A. Ortiz-Cadenas, I. Garcia-De La Torre et al., “Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes,” British Journal of Diabetes and Vascular Disease, vol. 10, no. 6, pp. 292–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Matsuura, L. R. Lopez, Y. Shoenfeld, and P. R. J. Ames, “β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?” Autoimmunity Reviews, vol. 12, no. 2, pp. 241–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Prandoni, F. Bilora, A. Marchiori et al., “An association between atherosclerosis and venous thrombosis,” The New England Journal of Medicine, vol. 348, no. 15, pp. 1435–1441, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. P. Prandoni, A. Ghirarduzzi, M. H. Prins et al., “Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis,” Journal of Thrombosis and Haemostasis, vol. 4, no. 9, pp. 1891–1896, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Prandoni, “Venous thromboembolism and atherosclerosis: is there a link?” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 270–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Ageno, C. Becattini, T. Brighton, R. Selby, and P. W. Kamphuisen, “Cardiovascular risk factors and venous thromboembolism: a meta-analysis,” Circulation, vol. 117, no. 1, pp. 93–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Piazza, S. Z. Goldhaber, D. M. Lessard, R. J. Goldberg, C. Emery, and F. A. Spencer, “Venous thromboembolism in patients with symptomatic atherosclerosis,” Thrombosis and Haemostasis, vol. 106, no. 6, pp. 1095–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Khemasuwan, Y. K. Chae, S. Gupta et al., “Dose-related effect of statins in venous thrombosis risk reduction,” The American Journal of Medicine, vol. 124, no. 9, pp. 852–859, 2011. View at Publisher · View at Google Scholar · View at Scopus